All In Biotech

NDA 216457 · Heron Theraps INC

Aponvie

Aprepitant · Intravenous · Substance P/Neurokinin-1 Receptor Antagonist

Novel

Last checked: Nov 20, 2026Latest source record: Mar 5, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2022

Sep 16, 2022

Approved uses

1

Original approval plus efficacy supplements

Registered trials

215

62 Phase 3, 9 recruiting

FAERS reports

7,377

7,064 serious, 1,464 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 1, 2026.

APONVIE is indicated for the prevention of postoperative nausea and vomiting (PONV) in adults. APONVIE is a substance P/neurokinin-1 (NK 1 ) receptor antagonist, indicated for the prevention of postoperative nausea and vomiting (PONV) in adults. Limitations of Use : APONVIE has not been studied for treatment of established nausea and vomiting. ( 1 ) Limitations of Use APONVIE has not been studied for the treatment of established nausea and vomiting.

Mechanism: Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK 1 ) receptors. Aprepitant has little or no affinity for serotonin (5-HT 3 ), dopamine, and corticosteroid receptors, the targets of existing therapies for postoperative nausea and vomiting (PONV). Aprepitant has been shown in animal models to inhibit emesis via central actions. Animal and human Positron Emission Tomography (PET) studies with aprepitant have shown that it crosses the blood brain barrier and occupies brain NK 1 receptors.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Sep 16, 2022 Original approval · Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated NovelLetterLabelReview
1 products under this application
  • APONVIE · APREPITANT 32MG/4.4ML (7.2MG/ML) · EMULSION, INTRAVENOUS · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Aprepitant" as an intervention, any sponsor and status, largest first.

All 215 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue1,287
  • nausea1,105
  • pyrexia921
  • off label use872
  • alopecia823
  • dyspnoea807
  • diarrhoea770
  • rash764
  • vomiting702
  • hypersensitivity701
  • pain690
  • infusion related reaction689

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20047
200515
200628
200724
200829
200948
201066
2011105
2012141
2013169
2014160
2015228
2016393
2017164
2018340
2019413
2020488
2021662
2022634
2023748
20241,026
2025889
2026600

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 324 on PubMed

Sponsor: Heron Theraps INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.